Melatonin alleviates traumatic brain injury-induced anxiety-like behaviors in rats: Roles of the protein kinase A/cAMP-response element binding signaling pathway

LING-LING XIE1, SHAN-SHAN LI2, YONG-JIAN FAN3, MAN-MAN Qi4 and ZHUANG-ZHUANG LI1

1Department of Pharmacy; 2Clinical Lab; Departments of 3Ultrasonography and 4Anesthesiology, Cangzhou Central Hospital, Cangzhou, Hebei 061000, P.R. China

Received May 22, 2021; Accepted October 21, 2021

DOI: 10.3892/etm.2022.11173

Abstract. Melatonin is a hormone produced by the pineal gland. Given its capabilities of neuroprotection and low neurotoxicity, melatonin could be a therapeutic strategy for traumatic brain injury (TBI). The present study was conducted to determine the neuroprotective effects of melatonin on TBI-induced anxiety and the possible molecular mechanism. Rats were randomly divided into seven groups. The rodent model of TBI was established using the weight-drop method. Melatonin was administered by intraperitoneal injection at a dose of 10 mg/kg after TBI. H89 (0.02 mg/kg), a special protein kinase A (PKA) inhibitor, or dibutyryl-cyclic adenosine monophosphate (cAMP; 0.1 mg/kg), an activator of PKA, were administered by stereotactic injection of the brain to evaluate the roles of PKA and cAMP-response element-binding protein (CREB) in melatonin-related mood regulation, respectively. At 30 days post-TBI, the changes in anxiety-like behaviors in rats were measured using the open field and elevated plus maze tests. At 24 h post-TBI, the number of activated astrocytes and neuronal apoptosis were evaluated using immunofluorescence assay. The expression levels of inflammatory cytokines (TNF-α and IL-6) in the amygdala were measured using an enzyme-linked immunosorbent assay. The expression levels of PKA, phosphorylated (p)-PKA, CREB, p-CREB, NF-κB and p-NF-κB in the amygdala were detected using western blotting. It was revealed that melatonin partially reversed TBI-induced anxiety-like behavior in rats, and decreased the number of activated astrocytes and neuronal apoptosis in the amygdala induced by TBI. H89 partially blocked the neuroprotective effects of melatonin; while dibutyryl-cAMP not only reduced the H89-induced emotional disturbance but also enhanced the protective effects of melatonin against TBI. Overall, melatonin can alleviate TBI-induced anxiety-like behaviors in rats. Moreover, the underlying mechanism may be associated with the activation of the PKA/CREB signaling pathway.

Introduction

Traumatic brain injury (TBI) is one of the primary causes of disability and death in young adults and children worldwide in a 2020 study (1,2). TBI not only causes major mechanical injury of cerebral tissues but also induces secondary mood changes, including anxiety, that persist for years post-injury and severely impair the quality of life for patients (3,4). The amygdala is prominently involved in neurobiological models of anxiety (5,6). To date, several pathological processes responsible for neuronal death, such as excitotoxicity, oxidative stress, inflammation and apoptosis, have been revealed to be involved in the secondary damage (cell death, excitotoxicity, oxidative stress and inflammation) of TBI (7,8). Neuroinflammation is characterized by glial activation (such as the microglia and astrocytes) and increased release of inflammatory substances within the brain, and it is important in short- and long-term neuronal injuries post-TBI (9). However, only a few effective strategies have been proven to improve the clinical prognosis of TBI (10).

Melatonin (N-acetyl 5-methoxytryptamine), a major product of the pineal gland, has been demonstrated to generate neuroprotective effects against a series of central nervous system (CNS) disease models, including cerebral ischemia (11), brain and spinal cord trauma (12) and subarachnoid and intracerebral hemorrhage (13). It possesses fundamental characteristics such as low neurotoxicity and high permeability in the blood-brain barrier (14). Previous studies have reported that melatonin ameliorates secondary injury (for example, by decreasing apoptosis, inflammation and oxidative stress) (15-17) and also improves functional deficits (such as memory, learning and motor activities). However, to the best of our knowledge, there is no clear information on the clinical therapeutic effects of melatonin in patients with TBI. Based on the aforementioned observations, the present study hypothesized that melatonin reduces neuronal injury induced by TBI.
The cyclic adenosine monophosphate/protein kinase A (cAMP/PKA) signaling pathway plays an important role in controlling the proliferation and differentiation of progenitor cells and the production of cytokines (18). It has been revealed that PKA phosphorylation is associated with CNS injury in vivo and in vitro (19). Furthermore, PKA plays an important role in the activation of the cAMP-response element-binding protein (CREB) (20). Activation of the PKA/CREB signaling pathway has been suggested to exert neuroprotective effects and to inhibit apoptotic cells in brain tissues (21). Therefore, regulation of amyloidloid PKA may reduce social avoidance and anxiety-like phenotypes (22). Moreover, melatonin administration ameliorates cerebral damage through the modulation of the phosphorylated (p)-AMPK/p-CREB signaling pathways and induces CREB activation correlated with long-term memory and cognition in vitro (23). p-CREB reduces neuroinflammation by regulating p-NF-kB and reducing the transcription of inflammatory mediators (24). However, the roles of the PKA/CREB signaling pathway in mood changes post-TBI, including depression and anxiety, remain obscure. Moreover, whether melatonin has the potential to be developed as a therapeutic strategy against TBI mediated by the PKA/CREB signaling pathway required investigation.

The present study was conducted to investigate the effects of melatonin on anxiety-like behaviors and the pathological changes in a rodent model of TBI. The present study also examined whether the PKA/CREB signaling pathway was involved in the neuroprotective effects of melatonin.

Materials and methods

Experimental animals. Adult male Sprague-Dawley rats (n=228; 6-8 weeks old) weighing 300-350 g were purchased from Liaoning Changsheng Biotechnology and raised at a stable temperature (25±1°C), humidity (50±10%) in a 12-h light/12-h dark alternating cycle with free access to food and water. The present study was approved by the Animal Review Board of Cangzhou Central Hospital [Cangzhou, China; approval no. 2020-013-02(Z)]. All animal experiments were performed according to the standards of the Institutional Animal Care and Use Committee at the Cangzhou Central Hospital. The animal health and behavior were monitored every day.

Once behavioral tests were finished, the rats were euthanized by intraperitoneal injection (i.p) of sodium pentobarbital (200 mg/kg). If rats were still alive after the experiments, euthanasia was conducted. If the rats lost their appetite for 5 days or stopped drinking for 3 days, lost >20% of their body weight and were unable to eat and drink before the scheduled experimental endpoint, euthanasia was also conducted. Electrocardiographic monitoring (straight lines) was used to detect the death of rats.

Group assignment and drug treatment. In experiment series 1, adult male Sprague-Dawley rats were randomly divided (computer-based randomization) into one of the following four groups: i) Sham; ii) TBI; iii) TBI + Mel (melatonin); and iv) TBI + S (saline). Melatonin (10 mg/kg) was dissolved in saline containing 2% ethanol was administered through i.p immediately after TBI in the TBI + S group.

In experiment series 2, adult male Sprague-Dawley rats were randomly assigned to one of the following groups: i) TBI + Mel + S; ii) TBI + Mel + H89; and iii) TBI + Mel + dibutyryl-cAMP (dbcAMP). H-89 (0.2 mg/100 g; cat. no. HY-15979A; MedChemExpress) is a potent and selective inhibitor of PKA (26). DbcAMP (1 mg/100 g; cat. no. HY-B0764A; MedChemExpress) selectively activates cAMP-dependent protein kinase (PKA) (27). H89 and dbcAMP were dissolved in saline (containing 10% dimethyl sulfoxide and 20% sulfobutylether β-cyclodextrin) and were applied by stereotactically injection 15 min before surgery. After anesthesia with sevoflurane (3-4%), a hole was made with microbore dental drill, then stainless-steel guide cannulae (28-gauge) were stereotactically injected to bilaterally target the amygdala (2.8 mm posterior to the bregma, 5.3 mm lateral from the midline and 6.25 mm ventral from the skull surface). To observe the interaction of H89 or dbcAMP on melatonin, the Sham, Sham + Mel + H89 and Sham + Mel + dbcAMP groups were established. Melatonin, H89, and dbcAMP were administered as aforementioned (Fig. 1). The number of animals required for each experiment in each group and the total number of animals were detailed in Table I.

TBI model. TBI was established using the weight-drop (WD) method (9,28). The animals were placed on a platform covered with foam and anesthetized with sevoflurane (7-8% for induction, and 3-4% for maintenance). A bone window with a diameter of 6-mm was drilled (3.5 mm behind the bregma and 2.5 mm to the right of the midline). A stainless-steel planchet (diameter, 6-mm; thickness, 5-mm) was attached. An iron weight (20 g) was freely dropped from a height of 25 cm, and the dura was kept intact. In sham-operated animals, the skull was exposed under anesthesia and skin incisions were then closed using silk sutures without TBI. Rats in the TBI or Sham group were treated by another experimenter blinded to behavioral tests.

Open field test (OFT). The OFT was performed to evaluate anxiety and inquiry behavior (29). The site was a large open field (60x60x40 cm), which was segmented into 16 equal squares. The test was conducted at 30 days post-TBI. The site was cleaned with 75% alcohol to prevent foreign smells that may influence behavior. The rat was positioned in the site, and the distance, speed, the number of squares crossed (with the same size at 90˚ angles to each other. The maze was 70-cm high from the floor. At 30 days post-TBI the rat was placed in the center zone of the maze with its nose directed toward the same open arm and allowed to explore the maze for 5 min. The maze was cleaned with 75% ethanol after each test. The time spent on the open and closed arms, the distance traveled and the number of entries were recorded and
analyzed using the software (XR-XG2011; Shanghai XinRuan Information Technology Co. Ltd.). An entry was calculated when all four paws were entered into an arm. The anxiety level was evaluated by counting the percentage of open arm entries (number of open arm entries/number of all arm entries) and the percentage of open arm time (time spent in the open arms/total time spent in all arms). The locomotor activity was evaluated using the total moving distance in the maze. Once behavioral tests (OFT and EPM) were finished, euthanasia was conducted by intraperitoneal injection of sodium pentobarbital (200 mg/kg).

**Immunofluorescence.** At 24 h after TBI, rats were anaesthetized with sevoflurane (8%) and transcardially perfused with cold PBS followed by 4% formaldehyde. The cerebral tissues containing the amygdala were fixed in 10% neutral-buffered formalin at 25°C for 24 h, embedded in solid paraffin and cut into a thickness of 4-µm (n=6). The paraffin sections were dewaxed, washed with ethanol for 2 min at 25°C and hydrated (100% ethanol for 3 min, 95% ethanol for 2 min, 80% ethanol for 2 min, 75% ethanol for 2 min, H2O for 1 min) at room temperature, blocked using QuickBlock™ Blocking Buffer (P0222; Beyotime Institute of Biotechnology) for 1 h at room temperature, blocked using QuickBlock™ Blocking Buffer (P0222; Beyotime Institute of Biotechnology) for 1 h at room temperature, and then incubated overnight at 4°C with the primary polyclonal mouse antibody against neuronal nuclei (NeuN, 1:200, ab104224; Abcam). After washing with PBS, the sections were incubated with TdT enzyme including a fluorescent labeling solution [One-step TUNEL cell apoptosis detection kit (fluorescent green); cat. no. C1088; Beyotime Institute of Biotechnology] at 37°C for 60 min in the dark. Subsequently, 5 µg/ml of Antifade Mounting Medium with 4',6-diamidino-2-phenylindole (DAPI; cat. no. P0131; Beyotime Institute of Biotechnology) was used for 3 min at 25°C to label the cell nuclei locations. Immunofluorescence images were captured using a fluorescence microscope (Olympus Corporation). A total of 6 fields of view were evaluated in each tissue section (x400 magnification). The position of amygdala was defined according to the corresponding brain anatomical map stained with DAPI (Fig. S2), which was ~5.3 mm from the midline and 6.25 mm from the parietal cortex. The number of GFAP-positive cells, the number of activated astrocytes and the percentage of NeuN- and TUNEL-positive cells were calculated by Image-pro plus 6.0 software (Media Cybernetics, Inc.).

**Western blotting.** At 24 h post-TBI, rats were anaesthetized with sevoflurane (8%) and transcardially perfused with cold PBS, total protein was extracted from the amygdala tissues and lysed in lysis buffer (PBS) and incubated with the corresponding secondary antibodies (Cy3-conjugated goat anti-mouse IgG; 1:500; cat. no. A0521; Beyotime Institute of Biotechnology) for 1 h at 25°C in the dark. Neuronal apoptosis was detected using TUNEL staining. After dewaxing and hydration as aforementioned, the slices were washed three times in PBS before adding 20 µg/ml of Proteinase K (cat. no. st533; Beyotime Institute of Biotechnology) at 37°C for 35 min. The slices were then incubated overnight at 4°C with the primary polyclonal mouse antibody against neuronal nuclei (NeuN, 1:200, ab104224; Abcam). After washing with PBS, the sections were incubated with TdT enzyme including a fluorescent labeling solution [One-step TUNEL cell apoptosis detection kit (fluorescent green); cat. no. C1088; Beyotime Institute of Biotechnology] at 37°C for 60 min in the dark. Subsequently, 5 µg/ml of Antifade Mounting Medium with 4',6-diamidino-2-phenylindole (DAPI; cat. no. P0131; Beyotime Institute of Biotechnology) was used for 3 min at 25°C to label the cell nuclei locations. Immunofluorescence images were captured using a fluorescence microscope (Olympus Corporation). A total of 6 fields of view were evaluated in each tissue section (x400 magnification). The position of amygdala was defined according to the corresponding brain anatomical map stained with DAPI (Fig. S2), which was ~5.3 mm from the midline and 6.25 mm from the parietal cortex. The number of GFAP-positive cells, the number of activated astrocytes and the percentage of NeuN- and TUNEL-positive cells were calculated by Image-pro plus 6.0 software (Media Cybernetics, Inc.).
proteins were transferred onto polyvinylidene fluoride membranes and blocked in Quickblock™ sealing fluid (cat. no. P0252; Beyotime Institute of Biotechnology) at 25˚C for 10 min, followed by incubation overnight at 4˚C with the indicated primary antibodies as follows: P-CREB (1:500; cat. no. AF5785), CREB (1:500; cat. no. AF1018), p-PKA (1:500; cat. no. AF1942), p-NF-κB (1:500; cat. no. AF5878), NF-κB (1:500; cat. no. AF7569) (all Beyotime Institute of Biotechnology) and GAPDH (1:2,000; cat. no. K106389P; Beijing Solarbio Science & Technology Co., Ltd.). The next day, the membranes were incubated with horseradish peroxidase AffiniPure goat anti‑rabbit IgG (H + L; 1:1,000; cat. no. A0208; Beyotime Institute of Biotechnology) at 37˚C for 1 h. Anti‑GAPDH Polyclonal Antibody (1:2,000; cat. no. K106389P; Beijing Solarbio Science & Technology Co., Ltd.) was used as an internal reference. The polyvinylidene fluoride membranes were incubated with ECL reagent (cat. no. P0018FM; Beyotime Institute of Biotechnology) for 5 min at room temperature, and protein bands were detected by a western blot detection system (Gel Doc XRS; Bio‑Rad Laboratories, Inc.). The gray value of the protein bands was analyzed using the Image‑pro plus 6.0 software (Media Cybernetics, Inc.).

Enzyme‑linked immunosorbent assay (ELISA). At 24 h post-TBI, the rats were euthanized using 200 mg/kg sodium pentobarbital (i.p.) and the amygdala was separated. The TNF-α Assay (cat. no. PT516) and IL-6 Assay (cat. no. PI328) ELISA kits (both from Beyotime Institute of Biotechnology) were used to measure the levels of TNF-α and IL-6 in the amygdala according to the manufacturer's instructions.

Statistical analysis. All statistical analyses were conducted using SPSS Statistics (version 20.0; IBM Corp.). Data are presented as mean ± standard deviation (n=12 rats/group in behavioral test, n=6 rats/group in molecular and pathological tests). Levene's test was used to test the homogeneity of variance hypothesis. When identifying data heteroscedasticity, the logarithmic transformation was performed and the heteroscedasticity was corrected. The statistical significance between groups was evaluated using one‑way analysis of variance, followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Melatonin alleviates anxiety-like behaviors post-TBI. Behavioral tests (OFT and EPM) were performed to evaluate the effects of melatonin on anxiety-related behaviors. The behavioral assessments of all rats at 30 days after TBI are presented in Fig. 2. First, the results of OFT indicated that rats in all the TBI groups exhibited a decreased amount of movement; namely, a significantly shorter total distance, slower average speed, less rearing, fewer number of squares crossed and less time spent in the center compared with those in the Sham group (P<0.0001 vs. Sham; Fig. 2A‑F). However, melatonin administration after TBI exposure resulted in significantly increased moving distance, greater average speed, less rearing, fewer number of squares crossed and time spent in the center between rats in the TBI and TBI + S groups.
Next, the results of EPM indicated that rats in the TBI group exhibited a significant decrease in the percentage of open arm entries and the percentage of open arm time compared with rats in the Sham group (P<0.0001 vs. Sham; Fig. 2G-I). Melatonin could significantly increase the percentage of open arm entries and the percentage of open arm times (P<0.0001 vs. TBI; Fig. 2G-I). There were no significant differences in the total moving distance among the groups (Fig. 2J), which suggested that the locomotor activity of rats among the different groups in this test was not altered.

**Figure 2.** Melatonin alleviates anxiety-like behaviors post-TBI. Open field test at 30 days post-TBI of the experimental rats. (A) Trajectory map. (B) Total moving distance. (C) Average speed (D) Rearing times. (E) Number of squares crossed. (F) Percentage of time spent in the center. (G) Percentage of open arm entries (%). (H) Elevated plus maze at 30 days post-TBI of the experimental rats. (I) Percentage of time spent in open arms (%). (J) Total moving distance in elevated plus maze. n=12/group. ****P<0.0001. TBI, traumatic brain injury; Mel, melatonin; S, saline; ns, not significant.

Melatonin reduces neuronal apoptosis in the region of amygdala post-TBI. At 24 h post-TBI, neuronal apoptosis was further evaluated by TUNEL staining combined with NeuN staining. As presented in Fig. 3A and B, there were few TUNEL-positive cells in the Sham group. Compared with the Sham group, TBI caused a significant increase in the number of TUNEL- and NeuN-positive cells (P<0.0001 vs. Sham group; Fig. 3A and B). However, melatonin administration significantly reduced neuronal apoptosis in the amygdala and provided neuroprotective effects after TBI (P<0.0001 vs. TBI group; Fig. 3A and B).
In addition, there were no statistical differences in neuronal apoptosis between the TBI and TBI + S groups.

**Melatonin upregulates the activation of astrocytes in the region of amygdala post-TBI.** GFAP is a marker of mature and activated astrocytes. The results demonstrated that the number of GFAP-positive cells was significantly elevated at 24 h post-TBI compared with that in the Sham group (P<0.0001 vs. Sham, Fig. 3C and D). However, the number of GFAP-positive cells significantly decreased in the TBI + Mel group (P<0.001 vs. TBI; Fig. 3C and D). Moreover, no statistical difference was observed in the number of GFAP-positive cells in the region of amygdala between rats in the TBI and TBI + S groups.

**Melatonin reduces the level of inflammatory cytokines and activates the PKA/CREB signaling pathway in the amygdala post-TBI.** The effects of melatonin on inflammatory cytokine levels were evaluated by ELISA. The results indicated that the levels of TNF-α and IL-6 in the TBI group were significantly increased compared with those in the Sham group (P<0.0001 vs. Sham; Fig. 4A and B). Melatonin administration significantly downregulated the expression levels of TNF-α and IL-6 compared with those in the TBI group (P<0.01 vs. TBI; Fig. 4A and B).

To further understand the mechanism of action of melatonin on anxiety-like behaviors, the protein expression levels of PKA, CREB and NF-κB and the phosphorylation levels of the three proteins in the amygdala tissues were detected using western blotting. The expression levels of p-PKA, p-CREB and p-NF-κB significantly increased in the TBI groups compared with those in the Sham groups (P<0.001 vs. Sham; Fig. 4C-F). The p-PKA/t-PKA ratio and the p-CREB/t-CREB ratio were also significantly higher in the TBI + Mel group compared with the TBI group (P<0.01 vs. Sham; Fig. 4C-E). In addition, the expression of p-NF-κB/t-NF-κB ratio was significantly decreased in the TBI + Mel group compared with that in the TBI group (P<0.0001 vs. Sham; Fig. 4C and F). There was no difference between the TBI and TBI + S groups in the expression of each protein.

**Melatonin may alleviate TBI-induced anxiety-like behaviors through the PKA/CREB signaling pathway.** Whether the exact
mechanism of action of melatonin against anxiety-like behaviors post-TBI was associated with the PKA/CREB pathway was also determined. H89 and dbcAMP were administered 15 min before TBI exposure. There was no difference among the Sham, Sham + Mel + H89 and Sham + Mel + dbcAMP groups in terms of open field and elevated maze tests (Fig. S1). Therefore, it was hypothesized that there was no interaction of H89 or dbcAMP with melatonin, and the three groups were eliminated in following experiment. There was a significant decrease in total moving distance, average speed, time spent in the center, number of squares crossed and rearing times in the OFT in the rats of the TBI + Mel + H89 group (P<0.0001 vs. TBI + Mel + S; Fig. 5A-F). The EPM results revealed that the rats in the TBI + Mel + H89 group exhibited a significant decrease in the percentage of open arm entries and the percentage of open arm times (P<0.0001 vs. TBI + Mel + S; Fig. 5G-I). However, after the activation of PKA with dbcAMP, the protective effect of melatonin on the nervous system was strengthened and exhibited the opposite effect of H89 application.

The effects of melatonin on inflammatory cytokine levels in the amygdala were measured by ELISA. Results revealed that the levels of TNF-α and IL-6 in the TBI + Mel + H89
Figure 5. Effects of the administration of H89 and dbcAMP on the anxiety-like behaviors of melatonin-treated TBI rats. OFT was performed at 30 days post-TBI of the experimental rats. (A) Trajectory map. (B) Total moving distance. (C) Average speed. (D) Rearing times. (E) Number of squares crossed. (F) Percentage of time spent in the center. (G) Elevated plus maze at 30 days post-TBI of the experimental rats. (H) Percentage of open arm entries (%). (I) Percentage of time spent in open arms (%). (J) Total moving distance in EPM. n=12 rats per group. **P<0.01, ***P<0.001, ****P<0.0001. TBI, traumatic brain injury; Mel, melatonin; S, saline; ns, not significant; dbcAMP, dibutyryl-cAMP.

group were significantly increased compared with those in the TBI + Mel + S group (P<0.05 vs. TBI + Mel + S; Fig. 6). DbcAMP application (TBI + Mel + dbcAMP) significantly downregulated the expression levels of inflammatory cytokines compared with those in the TBI + Mel + S (P<0.05; Fig. 6) and TBI + Mel + H89 groups (P<0.0001; Fig. 6).
Furthermore, the results revealed that H89 pretreatment before TBI in the TBI + Mel + H89 group induced significant decreases in the levels of p-PKA (P<0.05 vs. TBI + Mel + S; Fig. 7A and B) and p-CREB (P<0.0001 vs. TBI + Mel + S;...
Fig. 7A and C) in the amygdala compared with those in the TBI + Mel + S group. It was also revealed that the expression levels of p-NF-xB were significantly increased in the TBI + Mel + H89 group compared with those in the TBI + Mel + S group (P<0.0001 vs. TBI + Mel + S; Fig. 7A and D). Although the expression levels of p-PKA and p-CREB were significantly elevated (P<0.001), the expression level of p-NF-xB significantly declined in the TBI + Mel + dbcAMP group compared with that in the TBI + Mel + S and TBI + Mel + H89 groups (P<0.001; Fig. 7A-D). These findings revealed that melatonin could activate the PKA/CREB signaling pathway, whereas PKA inhibitors could partially reverse the neuroprotective effects of melatonin, which further aggravated the anxiety-like behavior and the release of inflammatory cytokines compared with those in the TBI + Mel + S group.

Discussion

TBI, represented by acute neurological injury, is considered to be a trigger for chronic traumatic disorders, including Alzheimer’s disease and Parkinson’s disease. However, no drug is currently available to effectively prevent these complications (30-32). Although previous studies have reported the involvement of anti-inflammation in the neuroprotective effects of melatonin (25,33), the underlying molecular mechanisms remain unclear. The present study demonstrated the following primary novel findings: i) Melatonin decreased neuronal apoptosis in the amygdala post-TBI; ii) melatonin alleviated anxiety-like behaviors post-TBI; and iii) inhibition of p-PKA using H89 revealed that the protective effects of melatonin could be partially reversed post-TBI. To the best of our knowledge, the present study is the first to support the significance and important functions of PKA inhibition in the development of anxiety-like behaviors after TBI exposure to date.

TBI is likely linked to long-term emotional disorders such as depression and anxiety (34). A previous report indicated that in the developing brain, mild-to-moderate TBI results in early behavioral and metabolomics changes (35). The present study revealed that TBI caused anxiety-like behaviors in rats. The results demonstrated that the amount of rearing and number of squared crossed, as well as the average speed and total moving distance, were significantly decreased in the OFT. Moreover, there was a significant increase in the amount of time spent stationary in corners. Melatonin administration could relieve anxiety-like behaviors in rodents, but the protective effects of melatonin could be partially eliminated after the administration of PKA inhibitors. The amygdala is part of the limbic system of brain tissue that produces, recognizes and regulates emotions (36). The amygdala is prominently involved in a neurobiological model of anxiety (37). Therefore, the present study selected the amygdala as the focus of investigation in the primary research.

Recently, there is growing evidence indicating that melatonin is a potential antioxidant considered as a protectant against TBI (15). Due to this beneficial role, the present study explored the underlying mechanism by which melatonin protects the brain. The dose of melatonin (10 mg/kg, i.p) in the present study was based on a previous study (10), as well as our preliminary experiments. Intervention should be initiated as soon as possible after TBI, preferably within 4 h after injury, to achieve maximum neuroprotective effects (38); therefore, the time point of melatonin treatment used in the present study was 0 h post-TBI.

Astrocytes are the most abundant glial cells in the CNS and are traditionally considered as the only structural elements supporting the structure of the brain (39). However, the importance of astrocytes in the survival of neurons has been proposed in recent years (40,41). In addition, drastically increased GFAP and allograft inflammatory factor 1 expression levels have been reported in the WD model of TBI (42). Astrocytes respond to TBI by activating the NF-kB pathway, which can result in the secretion of cytokines (43). For example, a study has demonstrated that reactive astrocytes may intensify inflammatory processes, if astrocytes exposed to an inflammatory stimulus produce proinflammatory cytokines such as IL-1β and TNF-α (44). IL-6-knockout can significantly reduce the neurological damage after TBI (45). Moreover, inhibition of TNF-α signaling can decrease neuronal apoptosis (46).

There are two main sources of inflammatory cytokines: One is the secretion of neutrophils and macrophages in the peripheral circulatory system, and the other is the microglia, astrocytes, oligodendrocytes and damaged neurons from the CNS. The present study aimed to explore the effects of melatonin on anxiety-like behaviors, neuronal apoptosis and astrocyte activation induced by TBI in rats. It was hypothesized that astrocyte activation might release more inflammatory cytokines, so the expression levels of TNF-α and IL-6 in cerebral tissues were tested. The present study revealed that astrocyte activation was increased in rats with TBI accompanied by increased neuronal apoptosis; moreover, after melatonin administration, the numbers of apoptotic neurons and activated astrocytes post-TBI were decreased. Furthermore, melatonin alleviated the anxiety-like behaviors induced by TBI. Therefore, it was hypothesized that the improvement of emotional changes induced by melatonin was associated with reduction of neuronal apoptosis and astrocyte activation.

Several previous studies have reported that the PKA/CREB signaling pathway is involved in apoptosis and correlates with cognitive function (47,48). Activation of PKA/CREB signaling plays an important role in reducing neuronal death or neurotoxicity (21). Another previous study suggested that CREB activation also decreases the apoptosis of neuroblastoma cells (49). The present study demonstrated that pretreatment with H89, a special inhibitor of PKA, significantly decreased the expression levels of p-PKA and CREB, increased the expression levels of IL-6 and TNF-α and reversed the improvement of anxiety-like behaviors induced by melatonin. However, pretreatment with dbcAMP, a PKA activator, further improved the anxiety-like behavior of rats. Overall, these results indicated that melatonin could alleviate the neuronal damage induced by TBI through the PKA/CREB signaling pathway. However, cAMP acts directly on three main effectors: PKA, protein directly activated by c-AMP (EPAC) and cyclic nucleotide-gated channels (50). In the hippocampus, EPAC contributes to the control of neuronal growth and differentiation and has been implicated in memory and learning as well as in anxiety and depression (51). Therefore, the role of EPAC in the findings in the present study cannot be ruled out.

The present study had several limitations. The experiments were limited only to the amygdala region, and changes
in the ventromedial prefrontal cortex and hippocampus remain unexplored. The specific pathway of apoptosis, such as the expression of Bcl-2 and Bak, should be investigated in future experiments. CREB is a downstream factor of PKA, and the phosphorylation of PKA will directly affect the activation and phosphorylation of CREB. Lack of CREB inhibitor or knockdown experiments is another limitation of the present study.

To summarize, melatonin could alleviate TBI-induced anxiety-like behaviors in rats, and the underlying mechanism may be associated with activation of the PKA/CREB signaling pathway.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Medical Science Research Project of Hebei Province (grant no. 20211745).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

LLX and ZZL performed the experiments and drafted the manuscript. SSL, YJF and MMQ helped to conduct the design of study and acquired the data. ZZL performed the statistical analyses. LLX conceived the study and revised the manuscript. MMQ and ZZL confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Animal Review Board of Cangzhou Central Hospital [Cangzhou, China; approval no. 2020-013-02(Z)]). All animal experiments were performed according to the standards of the Institutional Animal Care and Use Committee at the Cangzhou Central Hospital.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


